Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual

Go back to Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual
(NYSE: OGN) Delayed: 13.75 -0.01 (0.07%)
Previous Close $13.76    52 Week High $8.00 
Open $13.75    52 Week Low $8.00 
Day High $13.77    P/E N/A 
Day Low $13.74    EPS $0.00 
Volume 2,555,624